Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Unknown 2Completed 2Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Gynecologic 1

Conditions

Ovarian Neoplasms 17Breast Neoplasms 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 4Fallopian Tube Neoplasms 4Sarcoma 3Neoplasms 3Solid Tumor 2Small Cell Lung Carcinoma 2Recurrence 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Cancer Metastatic 2Advanced Solid Tumors 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Stomach Neoplasms 1Sarcoma, Ewing 1SCLC, Extensive Stage 1Platinum-sensitive Relapsed Ovarian Cancer 1Osteosarcoma 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Kenny-Caffey syndrome, Type 1 1Her-2 Negative Breast Cancer 1Glioblastoma 1Fludzoparib" and Anti-angiogenic 1Female Breast Cancer Patients 1

Interventions

pembrolizumab 163Carboplatin 146Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 39sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × fluzoparib × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Fudan University

Phase 1/2 Unknown
125 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
32 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Fudan University

Phase 1/2 Unknown
140 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
98 enrolled
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡